Document is current

Article History

Accepted: 2 April 2025

First Online: 30 April 2025

Declarations

:

: All authors have received travel and lodging from CVRx LAL – consultant CVRx, Abbott, Impulse Dynamics V Raje – no relevant disclosures JPF – consultant for AstraZeneca, CVRx and Merck SMA – consultant for CVRx ASB—consultant CVRx PM— consultant: Abbott, CVRx, Daxor, Speaker: Lexicon, AstraZeneca DMY – consultant CVRx AA – no additional relevant disclosures AY—speaking honoraria and consulting fees from Bayer, Merck, Novo Nordisk, AstraZeneca, Bridgebio, and scPharmaceuticals PP—Consultant CVRx MF—supported by the NIH, Alleviant, Gradient, Reprieve, Sardocor, and Doris Duke. He is a consultant and/or has ownership interest in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Astellas, Audicor, AxonTherapies, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, Clinical Accelerator, CVRx, Daxor, Edwards LifeSciences, Echosens, EKO, Endotronix, Feldschuh Foundation, Fire1, FutureCardia, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, ISHI, Lumia Health, Medtronic, NovoNordisk, NucleusRx, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, Puzzle, ReCor, Scirent, SCPharma, Shifamed, Splendo, Summacor, SyMap, Terumo, Vascular Dynamics, Vifor Pharma, Vironix, Viscardia, Zoll BH – consultant for Johnson and Johnson/Abiomed, Abbott, CVRx, Impulse Dynamics, Daxor V Rao – no additional relevant disclosures AH – consultant for CVRx and Abbott KM – no additional relevant disclosures R Gupta – consultant for CVRx R Garcia – consultant for CVRx and Impulse Dynamics AR—no additional relevant disclosures NYR – Advisor for CVRx, Impulse Dynamics, Care Dx, Consultant: Daxor.